全文获取类型
收费全文 | 1984篇 |
免费 | 84篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 21篇 |
妇产科学 | 15篇 |
基础医学 | 223篇 |
口腔科学 | 31篇 |
临床医学 | 130篇 |
内科学 | 641篇 |
皮肤病学 | 102篇 |
神经病学 | 178篇 |
特种医学 | 42篇 |
外国民族医学 | 25篇 |
外科学 | 165篇 |
综合类 | 3篇 |
一般理论 | 1篇 |
预防医学 | 189篇 |
眼科学 | 6篇 |
药学 | 115篇 |
中国医学 | 9篇 |
肿瘤学 | 138篇 |
出版年
2023年 | 12篇 |
2022年 | 26篇 |
2021年 | 52篇 |
2020年 | 43篇 |
2019年 | 62篇 |
2018年 | 61篇 |
2017年 | 28篇 |
2016年 | 43篇 |
2015年 | 34篇 |
2014年 | 77篇 |
2013年 | 122篇 |
2012年 | 129篇 |
2011年 | 175篇 |
2010年 | 87篇 |
2009年 | 75篇 |
2008年 | 131篇 |
2007年 | 126篇 |
2006年 | 122篇 |
2005年 | 116篇 |
2004年 | 103篇 |
2003年 | 99篇 |
2002年 | 80篇 |
2001年 | 26篇 |
2000年 | 26篇 |
1999年 | 24篇 |
1998年 | 13篇 |
1997年 | 14篇 |
1996年 | 15篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 14篇 |
1991年 | 13篇 |
1990年 | 6篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 13篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1970年 | 2篇 |
1968年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有2082条查询结果,搜索用时 31 毫秒
91.
Muhammad Imran Tanweer Aslam Gondal Muhammad Atif Muhammad Shahbaz Tahira Batool Qaisarani Muhammad Hanif Mughal Bahare Salehi Miquel Martorell Javad Sharifi‐Rad 《Phytotherapy research : PTR》2020,34(8):1812-1828
Apigenin is an edible plant‐derived flavonoid that has been reported as an anticancer agent in several experimental and biological studies. It exhibits cell growth arrest and apoptosis in different types of tumors such as breast, lung, liver, skin, blood, colon, prostate, pancreatic, cervical, oral, and stomach, by modulating several signaling pathways. Apigenin induces apoptosis by the activation of extrinsic caspase‐dependent pathway by upregulating the mRNA expressions of caspase‐3, caspase‐8, and TNF‐α. It induces intrinsic apoptosis pathway as evidenced by the induction of cytochrome c, Bax, and caspase‐3, while caspase‐8, TNF‐α, and B‐cell lymphoma 2 levels remained unchanged in human prostate cancer PC‐3 cells. Apigenin treatment leads to significant downregulation of matrix metallopeptidases‐2, ?9, Snail, and Slug, suppressing invasion. The expressions of NF‐κB p105/p50, PI3K, Akt, and the phosphorylation of p‐Akt decreases after treatment with apigenin. However, apigenin‐mediated treatment significantly reduces pluripotency marker Oct3/4 protein expression which might be associated with the downregulation of PI3K/Akt/NF‐κB signaling. 相似文献
92.
Bahare Salehi Monica Butnariu Mihaela Corneanu Ioan Sarac Sanja Vlaisavljevic Dusanka Kitic Amirhossein Rahavian Amirreza Abedi Morteza F. Karkan Indra D. Bhatt Arvind Jantwal Javad Sharifi‐Rad Clia F. Rodrigues Miquel Martorell Natlia Martins 《Phytotherapy research : PTR》2020,34(4):769-787
Chronic pelvic pain syndrome (CPPS) can be triggered by a various types of gynecological, gastrointestinal, urological, and musculoskeletal disorders. Recently, the role of the central nervous system has proven to be an integral part on the development of any chronic pain syndrome, including CPPS. However, owing to the complex and heterogeneous etiology and pathophysiology of CPPS, the establishment of effective therapeutic interventions remains challenging for both physicians and patients. Nonetheless, recent studies have pointed that medicinal plants and their secondary metabolites can be effectively used in CPPS therapy, besides contributing to restore the patients' quality of life and potentiate the conventional CPPS management. In this sense, this review aims to provide a careful overview on the biomedical data for the use of medicinal plants use and their secondary metabolites on CPPS management. 相似文献
93.
94.
95.
D'Haens GR Panaccione R Higgins PD Vermeire S Gassull M Chowers Y Hanauer SB Herfarth H Hommes DW Kamm M Löfberg R Quary A Sands B Sood A Watermeyer G Watermayer G Lashner B Lémann M Plevy S Reinisch W Schreiber S Siegel C Targan S Watanabe M Feagan B Sandborn WJ Colombel JF Travis S 《The American journal of gastroenterology》2011,106(2):199-212; quiz 213
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indications for starting biological therapy, after surgical drainage of any sepsis. For fistulizing CD, the efficacy of IFX for inducing fistula closure is best documented. Unique risks of NAT account for its labeling as a second-line biological agent in some countries. Patients who respond to induction therapy benefit from systematic re-treatment. The combination of IFX with azathioprine is better than monotherapy for induction of remission and mucosal healing up to 1 year in patients who are na?ve to both agents. Whether this applies to other agents remains unknown. IFX is also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients who have a diminished or loss of response to anti-tumor necrosis factor (TNF) therapy may respond to dose adjustment of the same agent or switching to another agent. Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment. 相似文献
96.
Danese S Sans M de la Motte C Graziani C West G Phillips MH Pola R Rutella S Willis J Gasbarrini A Fiocchi C 《Gastroenterology》2006,130(7):2060-2073
BACKGROUND & AIMS: Angiogenesis is a critical component of neoplastic and chronic inflammatory disorders, but whether angiogenesis also occurs in inflammatory bowel disease (IBD) has yet to be established. We assessed mucosal vascularization, expression of endothelial alphaVbeta3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa. METHODS: Mucosal endothelium was immunostained for CD31 and factor VIII and quantified by digital morphometry. alphaVbeta3 expression was studied in vivo by confocal microscopy and in vitro by flow cytometric analysis of human intestinal microvascular endothelial cells (HIMECs). Vascular endothelial growth factor (VEGF), interleukin (IL)-8, and bFGF levels were measured in mucosal extracts and cells and angiogenic bioactivity shown by induction of HIMEC migration and the corneal and chorioallantoic membrane angiogenesis assays. RESULTS: Microvessel density was increased in IBD mucosa. Endothelial alphaVbeta3 was strongly expressed in IBD but only sporadically in normal mucosa and was up-regulated in HIMECs by VEGF, tumor necrosis factor alpha, and bFGF. IBD mucosal extracts induced a significantly higher degree of HIMEC migration than control mucosa, and this response was mostly dependent on IL-8 and less on basic fibroblast growth factor or vascular endothelial growth factor. Compared with normal mucosa, IBD mucosal extracts induced a potent angiogenic response in both the corneal and chorioallantoic membrane assays. CONCLUSIONS: These results provide morphological, phenotypic and functional evidence of potent angiogenic activity in both CD and UC mucosa, indicating that the local microvasculature undergoes an intense process of inflammation-dependent angiogenesis. Thus, angiogenesis appears to be an integral component of IBD pathogenesis, providing the practical and conceptual framework for anti-angiogenic therapies in IBD. 相似文献
97.
Francisco Torres-Bondia Farida Dakterzada Leonardo Galvn Miquel Buti Gaston Besanson Eric Grill Roman Buil Jordi de Batlle Gerard Piol-Ripoll 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2022,25(4):261
BackgroundBenzodiazepines (BZDs) and Z-drugs (BZDRs) are among the most prescribed medications for anxiety and insomnia, especially among older adults. Our objective was to investigate the association between the use of BZDRs and the risk of dementia.MethodsA community-based retrospective cohort study was conducted based on the data available from 2002 to 2015 in Catalan Health Service. This cohort included all BZDR users (N = 83 138) and nonusers (N = 84 652) older than 45 years. A minimum 5-year lag window and an adjustment for psychiatric problems were applied for the data analysis.ResultsThe hazard ratio (HR) for the risk of incident dementia among BZDR users was 1.22 (95% CI = 1.15 to 1.31). This risk was not significant after adjusting the data confounding factors (HR = 1.01; 95% CI = 0.94 to 1.08). We observed a higher risk with short-to-intermediate half-life BZDs (HR = 1.11; 95% CI = 1.04 to 1.20) and Z-drugs (HR = 1.20; 95% CI = 1.07 to 1.33) than for intermediate-to-long half-life BZDs (HR = 1.01; 95% CI = 0.94 to 1.08). We demonstrated a higher risk of incident dementia (HR = 1.23; 95% CI = 1.07 to 1.41 and odds ratio = 1.38; 95% CI = 1.27 to 1.50, respectively) in patients who received 91 to 180 defined daily doses (DDDs) and >180 DDDs compared with patients who received <90 DDD. Regarding patient sex, the risk of dementia was higher in women than in men.ConclusionWe found that the incidence of dementia was not higher among all BZDR users. Short half-life BZDs and Z-drugs increased the risk of dementia at the highest doses, especially in female patients, showing a dose-response relationship. 相似文献
98.
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area 总被引:2,自引:0,他引:2
Benito N Sued O Moreno A Horcajada JP González J Navasa M Rimola A 《Transplantation》2002,74(10):1381-1386
BACKGROUND: Treatment of latent tuberculosis infection (LTBI) with isoniazid is recommended for transplant recipients with positive tuberculin skin test (TST). However, TST could be an imperfect identifier of LTBI in this population. In addition, the risk of isoniazid hepatotoxicity could be high in liver transplant recipients (LTR). A retrospective cohort study was performed to evaluate the diagnosis and treatment of LTBI in LTR. METHODS: Charts of all 547 patients who received primary liver transplantation at a University Hospital in Spain between 1988 and 1998 were reviewed. RESULTS: TST was performed in 373 patients (71%) before transplantation. The result was positive in 89 (24%). The median follow-up after transplantation was 49 months. None of the TST-positive patients developed tuberculosis (TB), but 5 out of 284 patients with negative TST (1.76%) had active TB (P=0.6). Twenty-three patients received isoniazid as treatment of LTBI according to the decision of the attending physician. None of these patients developed TB, but 4 of them (17%) presented isoniazid hepatotoxicity. Among patients who did not receive isoniazid, 2 out of 21 (9.52%) with radiologic previous TB developed active TB versus 0.44% (2/452) among the remaining patients (relative risk [RR], 27.8, 95% CI, 3.2-147). CONCLUSIONS: Treatment of LTBI with isoniazid can not be recommended to LTR on the basis of a positive TST because it is an imperfect identifier of patients at risk of TB. LTR with radiologic features of previous TB are at higher risk of posttransplant active TB. Isoniazid-related hepatotoxicity is more frequent among LTR than in the general population. 相似文献
99.
100.
Esther Sapiña-Beltrán Gerard Torres Montserrat Martínez-Alonso Manuel Sánchez-de-la-Torre Maria Franch Carmen Bravo Juan F. Masa Miquel Felez Ana Maria Fortuna-Gutierrez Jorge Abad Francisco García-Río Luciano F. Drager Ronald Lee Chi-Hang Miguel Ángel Martínez-García Ferran Barbé Mireia Dalmases 《Archivos de bronconeumologia》2018,54(10):518-523